New Research by Dr. Raymond Douglas on Protecting Hearing with Teprotumumab Dosing in Thyroid Eye Disease Patients

In a groundbreaking presentation at the ASOPRS 57th Annual Fall Scientific Symposium held in New Orleans, Dr. Raymond Douglas, MD, PhD, unveiled research that challenges conventional dosing schedules for teprotumumab, the first FDA-approved treatment for thyroid eye disease (TED). This innovative approach aims not only to treat the condition effectively but also to safeguard the hearing of patients susceptible to auditory side effects.

TED is an autoimmune disorder that leads to complications such as eye bulging, inflammation, and sometimes debilitating double vision. While teprotumumab has offered significant relief for many, concerns about its impact on hearing have arisen, particularly given that about 10% of patients experience hearing-related side effects during clinical trials. For patients with pre-existing hearing loss, these concerns escalate, affecting nearly 50% of individuals in a high-risk category.

Research Highlights

Dr. Douglas's investigation centered on modifying the dosing schedule of teprotumumab infusions. Traditionally, patients receive eight infusions spaced three weeks apart. His research proposed extending this interval to six weeks for those with existing auditory issues, a change that could greatly enhance patient safety without compromising the treatment's efficacy.

The findings from this study were compelling. By increasing the interval between infusions, patients demonstrated a remarkable 60% lower likelihood of experiencing hearing deterioration. Specific data showed that nearly 45% of those adhering to the standard three-week regimen suffered significant hearing decline at 24 weeks, in stark contrast to just one in six patients on the six-week schedule. This suggests that a longer infusion period could mitigate the risks of auditory side effects in an at-risk population.

Crucially, the extended dosing schedule did not diminish the treatment’s effectiveness. Each group exhibited similar improvements in key clinical measures such as inflammation, eye bulging, and double vision—integral markers that assess the success of TED treatment.

A Message from Dr. Douglas

Dr. Douglas, who received the 2026 ASOPRS Outstanding Contribution Award alongside his collaborator Dr. Terry J. Smith, emphasized the importance of ongoing research and patient safety. He stated, “Patients living with hearing loss highlight auditory changes as their greatest concern. The results of our study suggest that for high-risk groups, spacing out infusions could protect hearing while still delivering treatment benefits.” He reminded practitioners to vigilantly monitor auditory functions throughout treatment, not just in the pre-treatment phase.

Study Parameters

The study evaluated 38 TED patients with confirmed hearing loss prior to any treatment, divided into two groups based on their infusion schedule preferences. It involved systematic audiometric testing pre-treatment and again at 24 weeks, allowing for a statistically robust comparison of auditory changes between the two intervals.

- Six-week schedule: 18 patients (average age 57)
- Standard three-week schedule: 20 patients (average age 57)

The study's results align with a rising acknowledgment of the need for auditory assessments to precede and accompany treatment with teprotumumab, framing a clearer path for patient safety going forward.

Next Steps in Research

Given its retrospective nature, Dr. Douglas noted the necessity for larger prospective studies to further validate these promising findings. The initial results support the idea that adjusting infusion intervals could be an adaptable strategy to enhance patient care in the realm of thyroid eye disease treatment.

Dr. Douglas's commitment to advancing TED treatments is evident through his continued dedication to research and patient advocacy, which reinforces the evolving landscape of therapeutic options available to affected individuals. With his pioneering work, Dr. Douglas not only contributes to scientific advancement but also enhances the quality of life for those grappling with thyroid eye disease and its accompanying challenges.

For further insights into Dr. Douglas's work and to explore more about teprotumumab, visit raymonddouglasmd.com.